Literature DB >> 6111334

The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.

J M Knox, M W Orr, R Allen, M G Gelder, D G Grahame-Smith.   

Abstract

1 The reliability of 5-hydroxytryptamine induced platelet aggregation responses in psychiatric patients treated with neuroleptic drugs was investigated by examining the effects of a number of technical factors which could account for the variability of responses observed in some patients. 2 Variation in incubation time, temperature, aggregometer stirrer speed, and in the time interval between withdrawal of the blood sample and testing, had no significant effects on the consistency of responses. 3 Dilution of platelet rich plasma (PRP) led to enhanced platelet aggregation responses becoming non-enhanced. 4 Overcentrifugation of blood samples during the preparation of PRP caused a decrease in the incidence of enhanced platelet aggregation responses observed in chronic schizophrenic patients receiving chlorpromazine. 5 The reliability of platelet aggregation responses as indices of the action of neuroleptic drugs in psychiatric patients remains doubtful.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6111334      PMCID: PMC1401612          DOI: 10.1111/j.1365-2125.1981.tb00531.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

2.  Platelet aggregation and chlorpromazine therapy.

Authors:  D J Boullin; J M Know; J R Peters; M W Orr; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

3.  The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.

Authors:  M W Orr; J M Knox; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.

Authors:  M W Orr; D J Boullin
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.

Authors:  D J Boullin; D G Grahame-Smith; R P Grimes; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

  5 in total
  3 in total

Review 1.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

2.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 3.  Human platelet 5-hydroxytryptamine receptors: binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration.

Authors:  D G Grahame-Smith; D P Geaney; M Schachter; J M Elliott
Journal:  Experientia       Date:  1988-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.